Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Megna

Showing results (71-80 of 381) with videos related to

Pageof 39
Sort By:
Expert Opinion on Investigational Drugs|May 27, 2023
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugsElisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Drug Safety|October 17, 2022
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledgeAngelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, et al.
Clinical, Cosmetic and Investigational Dermatology|January 13, 2025
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging AssociationFabrizio Martora, Teresa Battista, Antonella Giordano, et al.
Dermatologic Therapy|January 31, 2020
A case of erythrodermic psoriasis successfully treated with guselkumabMatteo Megna, Angelo Ruggiero, Elisa Camela, et al.
Dermatologic Therapy|April 19, 2022
Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life studyMatteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Pediatric Health, Medicine and Therapeutics|November 29, 2023
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on BiologicsAngelo Ruggiero, Antonio Portarapillo, Matteo Megna, et al.
Medical Hypotheses|June 4, 2020
May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?Claudio Marasca, Angelo Ruggiero, Maddalena Napolitano, et al.
Clinical, Cosmetic and Investigational Dermatology|August 23, 2022
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World EvidenceAngelo Ruggiero, Vincenzo Picone, Fabrizio Martora, et al.
Clinical and Experimental Dermatology|December 11, 2023
Comment on 'Development of chilblain lesions during the COVID-19 pandemic is strongly associated with cold weather: a retrospective analysis of patients from a single centre in the USA'Luca Potestio, Fabrizio Martora, Matteo Megna, et al.
Dermatology and Therapy|September 6, 2018
Treatment of Atopic Dermatitis with Biologic DrugsGabriella Fabbrocini, Maddalena Napolitano, Matteo Megna, et al.
Pageof 39

Showing results (71-80 of 381) with videos related to

Sort By:
Pageof 39
Expert Opinion on Investigational Drugs|May 27, 2023
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugsElisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Drug Safety|October 17, 2022
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledgeAngelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, et al.
Clinical, Cosmetic and Investigational Dermatology|January 13, 2025
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging AssociationFabrizio Martora, Teresa Battista, Antonella Giordano, et al.
Dermatologic Therapy|January 31, 2020
A case of erythrodermic psoriasis successfully treated with guselkumabMatteo Megna, Angelo Ruggiero, Elisa Camela, et al.
Dermatologic Therapy|April 19, 2022
Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life studyMatteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Pediatric Health, Medicine and Therapeutics|November 29, 2023
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on BiologicsAngelo Ruggiero, Antonio Portarapillo, Matteo Megna, et al.
Medical Hypotheses|June 4, 2020
May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?Claudio Marasca, Angelo Ruggiero, Maddalena Napolitano, et al.
Clinical, Cosmetic and Investigational Dermatology|August 23, 2022
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World EvidenceAngelo Ruggiero, Vincenzo Picone, Fabrizio Martora, et al.
Clinical and Experimental Dermatology|December 11, 2023
Comment on 'Development of chilblain lesions during the COVID-19 pandemic is strongly associated with cold weather: a retrospective analysis of patients from a single centre in the USA'Luca Potestio, Fabrizio Martora, Matteo Megna, et al.
Dermatology and Therapy|September 6, 2018
Treatment of Atopic Dermatitis with Biologic DrugsGabriella Fabbrocini, Maddalena Napolitano, Matteo Megna, et al.
Pageof 39